4.1 Article

ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST)

Journal

BMJ CASE REPORTS
Volume 14, Issue 6, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bcr-2021-243931

Keywords

venous thromboembolism; COVID-19; vaccination; immunisation; headache (including migraines); haematology (incl blood transfusion)

Ask authors/readers for more resources

A healthy 27-year-old man developed significant cerebral venous sinus thrombosis and acute parenchymal bleed following vaccination with the ChADOx1 nCOV-19 vaccine. Despite aggressive medical and surgical management, his intracranial pressures remained high and his brain injury was deemed unsurvivable.
A 27-year-old fit and well man presented with intermittent headaches associated with eye floaters and vomiting. His symptoms started 48 hours after having the first dose of ChADOx1 nCOV-19 vaccine (Vaxzevria, previously AstraZeneca COVID-19 vaccine; AstraZeneca) and bloods showed raised D-dimer, low platelets and fibrinogen. CT venogram demonstrated significant cerebral venous sinus thrombosis. He was immediately started on intravenous immunoglobulins and dabigatran after liasing with haematologist. The next day, he complained of worsening headache and new homonymous hemianopia. Repeat CT of the head showed an acute parenchymal bleed with subdural extension and was given idarucizumab and high-dose steroids. He had an emergency decompressive craniotomy and external ventricular drain as his intracranial pressures were difficult to control. Despite full medical and surgical management, his intracranial pressures continued to rise and his brain injury was felt to be too devastating and was deemed unsurvivable.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available